4D Molecular Therapeutics (FDMT) Equity Ratio (2019 - 2025)
Historic Equity Ratio for 4D Molecular Therapeutics (FDMT) over the last 7 years, with Q3 2025 value amounting to 0.87.
- 4D Molecular Therapeutics' Equity Ratio fell 493.26% to 0.87 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.87, marking a year-over-year decrease of 493.26%. This contributed to the annual value of 0.91 for FY2024, which is 60.75% up from last year.
- 4D Molecular Therapeutics' Equity Ratio amounted to 0.87 in Q3 2025, which was down 493.26% from 0.89 recorded in Q2 2025.
- Over the past 5 years, 4D Molecular Therapeutics' Equity Ratio peaked at 0.95 during Q1 2024, and registered a low of 0.87 during Q3 2025.
- Its 5-year average for Equity Ratio is 0.91, with a median of 0.91 in 2025.
- As far as peak fluctuations go, 4D Molecular Therapeutics' Equity Ratio surged by 642.94% in 2024, and later plummeted by 633.7% in 2025.
- 4D Molecular Therapeutics' Equity Ratio (Quarter) stood at 0.9 in 2021, then dropped by 2.13% to 0.88 in 2022, then increased by 2.51% to 0.91 in 2023, then rose by 0.61% to 0.91 in 2024, then decreased by 4.49% to 0.87 in 2025.
- Its Equity Ratio stands at 0.87 for Q3 2025, versus 0.89 for Q2 2025 and 0.91 for Q1 2025.